Mushroom-derived (1→3),(1→6)-β-D-glucans exhibit diverse biological activities, including antitumor effects, which may be modulated through chemical modification. In the present study, sequential hydroxypropylations were performed on a highly purified (1→3),(1→6)-β-D-glucan (NM-Glc) from the mushroom Lactarius quieticolor to generate derivatives with distinct structural characteristics (HP1 and HP2). The derivatives were characterized by NMR, GC-MS, and SEC-MALS-RI, which revealed that the substitutions occur predominantly at the O-6 and O-4 positions. Each sample (NM-Glc (unmodified glucan; Mw 1.28 × 105 g.mol-1), HP1 (Mw 3.67 × 104 g.mol-1, MS: 0.70, DSFrac: 0.37, DSSub: 0.63), and HP2 (Mw 5.04 × 104 g.mol-1, MS: 0.94, DSFrac: 0.48, DSSub: 0.91)) was evaluated for its biological effects on B16-F10 murine melanoma cells at 10, 100, and 1000 µg.mL-1. Importantly, NM-Glc did not exhibit significant cytotoxicity toward tumor cells under the evaluated conditions, whereas the hydroxypropyl-modified glucans exhibited cytotoxicity at 100 and 1000 µg.mL-1 and reduced cell adhesion to the substrate (observed only for HP2 at 1000 µg.mL-1). AO/EB staining demonstrated that HP1 and HP2 induced apoptosis, with HP2 producing the most pronounced effects. Therefore, hydroxypropylation is a promising strategy to generate (1→3),(1→6)-β-D-glucans exhibiting antitumor effects in melanoma cells in vitro.